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ABSTRACT
With recent advances in chemotherapy, traditional
clinicopathological factors should not be used to exclude
otherwise resectable patients from surgery. Pathological or
clinical response to chemotherapy has become valuable in
determining the treatment for individual patients. Portal vein
embolization and two-stage operation with ablative therapy
and preoperative chemotherapy should be considered for
unresectable liver metastases located in a liver remnant that
is at the minimum volume required for survival. The recent
E0RTC 40983 trials regarding preoperative chemotherapy for
resectable CLM have failed to demonstrate a clear significant
advantage. However, patients with a low clinical risk score
for the recurrence, such as several metastases of less than 4
cm, and who are fit candidates for liver resection are often
offered immediate surgery. Patients at high clinical risk should
also be considered for neoadjuvant chemotherapy. One
forthcoming and appealing strategy is to adapt postoperative
treatment according to tumor response as evaluated by
neoadjuvant chemotherapy or by the presence of individual
tumor biomarker such as the Kras mutation or single-
nucleotide polymorphisms. This could avoid the
overtreatment of nonresponsive patients and enable a more
tailored approach to treat an individual patient’s disease. The
treatment paradigm for CLM is rapidly changing with the
development of newer anticancer chemotherapeutic agents.
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INTRODUCTION:
The second leading cause of cancer-related mortality
worldwide is colorectal cancer. In the United States, more
than 140,000 patients are diagnosed and 56,000 die of this
disease on early basis.[1] At the time of diagnosis 85% of
the patients are appropriate for resection at the time of
diagnosis and the disease recurs in more than 50% of the
patients in the first five years. Most frequently the
metastases affect the liver (in 30% to 60% of cases), and
the lung (in 20% to 30% of the cases). At presentation up
to 25% of colorectal cancer patients have liver metastases,
and a another 30% develop liver metastases usually until
the second year after primary tumor resection.[2] Leaved
without treatment the patients with colorectal liver
metastases have median survival  as 12 to 15 months and
5-year survival less than 5%. In spite of the introduction of
a many new agents the median survival for patients with
stage IV disease treated with the best chemotherapy remains
only 25 months.[3, 4] Liver resection remains the best option
for achieving long-term survival despite the new treatmen
modalities. No consensus is available on if aggressive
surgery is proper for CLM; there are some arguments the
survival benefit after this procedure is due to better patient
selection rather than of the treatment strategy. The tumor
biology is probably prevailing no matter of the treatment
applied. Therefore the only way to change the disease
course for some patients is complete hepatic resection for
CLM and  integrated therapy with surgery and systemic
chemotherapy is of increased importance. Patients with CLM
previously considered as unresectable now have a chance
for a curative resection because of the new development in
multimodality treatment. Now the 5-year overall survival rate
after surgery reaches 58%. [5–10]
EVALUATION OF LIVER SPREAD
A systematic and rigorous assessment of
preoperative liver is the careful selection of patients for
surgery. The detection of CLM has improved over the past
decade, and various imaging techniques are now available
for monitoring patients with colorectal cancer are available.
In general, thin slice multiphase helical computed
tomography (CT) is the preferred method of imaging for the
detection of CLM, as it is the technique most widely used.
It can be scan the chest, liver, abdomen and pelvis in the
same exam, and through the various stages of analysis
provides detailed anatomical associations of vascular tumors
and in planning the resection liver. A similar alternative that
is preferred by some centers is the magnetic resonance
imaging (MRI) with a combination of gadolinium and
contrast enhanced with superparamagnetic iron oxide.
Fluorodeoxyglucose positron emission tomography
(FDG-PET) appears to be a useful for the detection of
extrahepatic disease,[5] but is its ability to evaluate the liver
itself is limited because the detection of intrahepatic lesions
is poor, especially after chemotherapy.[11] A recent meta -
analysis showed that FDG-PET has better sensitivity in
detecting liver metastases of colorectal cancer (94.6%) than
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helical CT (64.7%) or MRI 1.5T (75.8%).[12] The lower
resolution of FDG-PET remains the disadvantage over CT
or MRI, and its specificity, particularly in patients, with
preoperative chemotherapy. Finally, FDG-PET provides no
anatomical details required for surgical planning. In this way,
the role of FDG-PET in patients with CLM can be
determined. Although some authors claim diagnostic
laparoscopy being beneficial to improving patient selection
for hepatic resection of CLM,[13] the improved preoperative
imaging gives the laparoscopic staging an inferior role. In
addition to a careful evaluation of the liver and extrahepatic
involvement, an accurate measurement of the liver is
mandatory in the evaluation of candidate patients for major
hepatectomy in order to evaluate the remnant liver and the
need for preoperative portal vein embolization.[14] Volumetric
data from are obtained from multiphasic CT imaging for the
staging and surgical planning. The concept of the liver
volume and the clinical significance are discussed later in
this article.
Definition of resectability
The main oncological contraindications for surgery
of the liver are the presence of unresectable liver disease
and the presence of extrahepatic disease (Table 1).
In the past, resection of CLM has been performed in
patients with more than three metastases, a negative
resection margin expected less than 1 cm, or extrahepatic
disease. However, recent studies have shown that long-term
survival is possible even in patients with these clinical and
pathological factors, and as such, the definition of
resectability has evolved from tumor characteristics, such
as tumor size and number to the possibility for complete
resection of both extra- and intrahepatic (R0 resection).
Another interpretation is that there is a shift away from
focusing on the tumor to what will be left after resection
(remnant liver). Currently, CLM should be considered
resectable if the patient has no underlying liver disease and
has at least two adjacent liver segments (not less than 20%
of the remnant liver) that can be preserved with an adequate
vascular flow, outputs and drainage of the bile ducts.[14,
15] The following sections are milestones in the discussion
about contraindications, including a discussion of
prognostic factors, selection factors and respectability.
Number of metastases
Multiple metastases and the presence of bilobar
disease correlate with a worse prognosis, especially in cases
where more than four metastases are involved, because this
case is associated with an increased risk of extrahepatic
disease and relapse after systemic surgery. In fact these
patients generally take a broad pre-operative investigation.
The use of FDG-PET may be particularly useful for detecting
extrahepatic disease in patients at high risk. Pawlik et al.[5]
recently reported on a cohort of 6 patients with more than
four metastases treated with multimodal therapy, including
preoperative chemotherapy. The 5-year disease-free survival
and overall survival was 22% and 51% respectively after
liver resection. Similarly, Kokudo et al,[16] reviewed patients
from Tokyo with a high number of metastases, established
that although the number of metastases is negative
prognostic the surgery for CLM is still the only curative
treatment.  Up to 70% and 80% of the liver can be resected
safely, and the mortality rate after liver resection is almost
zero.[17] Therefore, the number of metastases should not
be considered a contraindication for curative liver resection,
but a prognostic factor, able to be overcome by surgery and
systemic chemotherapy in selected patients
Surgical margin
Historically, at least 1 cm margin is required for safe
surgical resection. Resections with an expected margin of
less than 1 cm are often defined as “non radical” and
sometimes considered as a contraindication for resection.
Study of the real margin relapse showed that the margin of
1 cm is not beneficial to the probability of survival. In a
series of 557 patients multicenter report  by Pawlik et al,
showed that although the positive surgical margin (R1) there
is a slightly increased risk of local recurrence of the tumor
(11%) and the width cannot predict the increased risk of
margin recurrence or survival.[7] Similarly, other studies have
shown that non-anatomic resections, which are usually
associated with a minimum margin, are not associated with
an increased risk of local recurrence after surgery.[18, 19]
These studies have clearly shown that the expected minimum
margin should not be considered as an contraindication
against resection.
Tab. 1. Contraindications to resection of colorectal liver metastases
Relative Absolute
Extra hepatic metastases Peritoneal carcinomatosis
Colonic recurrence Multiple extrahepatic metastases
Solitary resectable peritoneal metastasis Inability to perform hepatic RO resection
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Hilar lymph nodes metastases
Whether resection of CLM is indicated in patients
with hilar and perihepatic lymph node metastases is
controversial. These lymph node metastases may predict a
poor prognosis after surgery for CLM. Jaeck et al.[20]
recently demonstrated that hilar and perihepatic lymph node
metastases have strong negative influence on prognosis in
comparison with multiple bilobar liver metastases, and that
they are related with increased level of carcinoembryonic
antigen, or even the presence of a solitary resectable
peritoneal disease. Therefore, the presence of hilar lymph
node metastases is usually a contraindication to resection
of CLM and could be considered a good indicator of the
need for preoperative chemotherapy in patients with
unresectable disease at presentation. However, the precise
role of lymphadenectomy during surgery for CLM needs to
be clarified.[14]
Extrahepatic spread
Several authors have reported the long-term survival
in patients with unresectable CLM and extrahepatic disease.
Elias et al.[21] found survival rate of 28% in 5 years for
patients with more than five metastases and extrahepatic
sites of several diseases treated with radical surgery. Other
studies have shown that long-term survival can be expected
after complete resection of pulmonary metastases of
colorectal cancer, even when metastases are detected in the
same time as CLM. Selection criteria for patients for lung
resection are under investigation. It is generally accepted,
however, that the patient be considered for lung resection
if it is technically feasible and there is no evidence of hilar
or paracardiac engagement. With strict selection criteria, the
operation of CLM with extrahepatic sites achieves survival
rate of 78% after 3 years and 56% after 5 years.[22]
Surgical technique
Some attempts have been clarify    the importance of
anatomic and non-anatomic (limited) partial liver resection
for CLM. A recent systematic review that compared the
results after limited resection vs. anatomical CLM showed
no difference in tumor clearance, relapse or long-term
survival.[25] In other words, the anatomic resection is not
superior to limited resection for CLM from an oncological
point of view. Applying the principle that the outcome
depends on complete resection of metastases both
anatomical resection and non-anatomic (or a combination)
should be used  eradicate the disease. This analysis
confirms the finding that the tumor biology and not the type
of resection is important for the prognosis.
Intraoperative ultrasound
Since its introduction before 20 years, it is widely
used by hepatobiliary surgeons.[26] Several studies have
shown that this method complements the preoperative cross-
sectional area. In experienced hands, IOU may show
additional lesions in 10% to 15% of patients, although
improvement of the preoperative studies can reduce of this
advantage of the IOU. More importantly, IOU is much
important for planning the parenchymal transection and the
relationship between the tumor and vascular structures and
intrahepatic bile to define the complete removal of the tumor
and preservation to ensure that vasculobiliary essential
structures.[27] The recent introduction of contrast-enhanced
IOU may improve intraoperative staging.[28]
Hemostasis
One of the most powerful and independent prognostic
factors after hepatic resection is the amount of blood loss
during surgery.[29, 30] Maintenance of low central venous
pressure, normally less than 5 mmHg has been shown to
reduce blood loss from hepatic veins and liver parenchyma
during liver transection.[31, 32] Different methods for
reduction of the intraoperative bleeding have also been
developed, such as continuous or intermittent pedicle
clamping (Pringle maneuver), tightening hemi-liver and total
vascular exclusion with or without clamping of the inferior
vena cava[33] The majority of elective resection can be
performed safely with intermittent pedicle clamping in general
and the use of total vascular exclusion is rarely necessary
and is usually[34-36] with hemodynamic changes resulting
in increased in postoperative morbidity and mortality. Newly
developed devices such as high frequency coagulants, saline-
linked cautery and ultrasonic dissectors allow hemostatic
parenchymal transection with minimal blood loss.[37]
However a prospective randomized study showed no
significant difference in blood loss when surgery was
performed using new devices for dissection or traditional
crush technique.[38] The contribution of postoperative
anesthesia is also remarkable. The use of continuous epidural
anesthesia provides optimal pain control so that the lung
function is improving (used to be a problem in patients with
upper abdominal incision), and leads to early mobilization of
patients, which significantly reduces morbidity.
SHORT TERM AND LONG-TERM RESULTS
Hepatic resection is a well established procedure, with
a mortality rate of less than 5% and morbidity less than 30%
to 40%. Important factors for poor prognosis after liver
resection are intraoperative bleeding, perioperative
transfusions, insufficient remnant liver and infectious
complications. These conditions can be devastating if lead
to liver failure, which occurs in less than 4% of cases.
Proper patient selection, meticulous technique and careful
intraoperative and postoperative management are essential
to minimize surgical complications. Table 2 shows the long-
term results of several published series number of liver
resection for CLM, and includes the most important
predictors of relapse.[5, 7-9, 19, 39-48]234  / JofIMAB 2012, vol. 18, book 1 /
As reported despite the growing number of resections
for CLM, the survival rate at 5 years is now over 51% to 58%
in mono-and multi-institutional studies.[5-10] Interestingly,
recent studies with patients with advanced multiple and
bilateral disease, which was considered not suitable for
resection until a few years, the preoperative systemic
chemotherapy has proven to achieve long-term survival. The
most important clinicopathological factors, which are useful
for the prediction of prognosis after liver resection for CLM,
are the margin status, the level of the colon tumor and primary
location, preoperative carcinoembryonic antigen level, size
and number of lesions and the presence or absence of
extrahepatic metastases. These prognostic factors determined
before the advent of effective systemic chemotherapy, but
their relevance as prognostic indicators in this new era of
management CLM is unknown. With advances in molecular
biology techniques factors such as hTERT are potential
prognostic indicators and emerging markers may become more
accurate than clinical factors.[23]
New tactics to improve resectable cases
Advances in systemic chemotherapy combinations in
conjunction with advances in surgical technique and patient
selection has improved considerably the population of
patients with potentially curative resection of CLM can be
expanded. Examples of relatively new techniques include
preoperative chemotherapy, portal vein embolization, two-
stage hepatectomy for bilateral liver metastases, extended
hepatectomy, and repeat hepatectomy. Many patients who
were unsuitable for resection, only a few years ago would be
classified, now with preoperative chemotherapy,
cytoreductive surgery followed by liver treats.
Neoadjuvant chemotherapy
The development of new, more effective
chemotherapeutic agents has led to a significant increase in
survival benefit in patients with inoperable colon cancer stage
IV. Oxaliplatin and irinotecan, which are usually used in
conjunction with therapies based on 5-Fluorouracil/Folinic
acid can shrink the liver metastases,control the potential sites
of extrahepatic disease [49] and allow subsequent resection
of residual disease. The indications for preoperative systemic
chemotherapy are the risk factors for recurrence, such as
tumor size, number of tumors, disease-free interval and the
presence or absence of extrahepatic disease. The increased
use of preoperative chemotherapy is a clinical dilemma,
whether to prescribe or not a preoperative chemotherapy in
patients with initially resectable disease. This dilemma is not
only academic, because recent reports indicate an increased
risk of adverse post-treatment excision events in patients with
preoperative systemic chemotherapy. Liver damage such as
steatosis and steatohepatitis in irinotecan-treated patients
has been described and also intra-vascular damage, such as
sinusoidal obstruction in patients treated with oxaliplatin have
been reported.[50, 51] These chemotherapy-related liver injury
reduce the ability of the hepatocytes to regenerate in response
to major hepatectomy by changes in nuclear factors such as
nuclear factor kappa B (NF-kB), which is crucial for the primal
Tab. 2. Table 2. Predictors of recurrence and long-term survival after resection for colorectal liver metastases
R1 Synchronous Primary Size of No. Preoperatlve Extraliepatic 5-Year
Author, Year Status Presentation Nodes + Metastases Metastases CEA Disease Survival
Fernandez, 20045 ---+- 5 8 %
Pawlik.20057 + - - + + + 58%
Abdalla, 20048 + - + + 58%
Choti.20029 + ---++ 5 8 %
Elias, 199819 + + - - - - - 28%
Gayowski, 199439 + + + - + - + 32%
Scheele, 199540 + + + + - - - 40%
Nordlinger, 199641 + + + + + + 28%
Jaeck, 199742 + + + + + + - 26%
Jamison, 199743 - - - 32%
Jenkins, 199744 + - - + 25%
Ambiru, 199945 + - + + + 23%
Fong, 199946 + + + + + 46%
Minagawa, 200047 - - - + - - 38%
Figueras, 200148 + - + + + 53%
CEA, Carcinoembryonic antigen.  / JofIMAB 2012, vol. 18, book 1 /  235
stage of liver regeneration. This leads to an increased
postoperative morbidity and even mortality. Although
resection has proven to be safe after preoperative
chemotherapy, the mortality rate is [52, 53] increased in certain
types of liver damage associated with chemotherapy,
specifically, steatohepatitis associated with irinotecan
therapy.[54] The preoperative chemotherapy should be
carefully applied in patients with resectable disease, because
the development of intra-hepatic complications may require
a change in surgical strategy or even exclude surgery as a
treatment option at all. Faced with this clinical dilemma,
molecular markers are needed to predict which patients will
respond better to preoperative chemotherapy and which
drugs or drug classes will be more effective and better
tolerated by a particular patient.
Portal vein embolization
Portal vein embolization (PVE) in preparation for major
hepatic resection has been shown to induce hypertrophy of
the remnant liver and reduce the risk of postoperative liver
failure after major hepatectomy.[55] PVE has become part of
clinical practice in Japan for patients with primary liver cancer
and helps to improve resectability rates of liver cancer.[56,
57] Ipsilateral PVE is usually performed through a
percutaneous transhepatic approach by ultrasound-guided
puncture of a portal branch embolization of the liver part
planned for resection. There is a variety of substances used
for embolization, e.g. absolute alcohol,  ethiodized oil,
cyanoacrylate with no clear difference between them.[58] PvE
is a well tolerated procedure. In our series of 112 cases, the
complication rate is 8.9% and includes hematoma, partial
thrombosis of the portal vein, esophageal bleeding and
migration of embolization agent. Only one patient was
considered inoperable because of PVE complications, but he
also had tumor progression, which presented as a
contraindication to resection. Indications for PVE are based
on the standardized future liver remnant (sFLR) and the
presence or absence of underlying liver disease. The sFLR
is measured by the ratio between the sFLR and the total liver
volume (TLV). The sFLR calculated by volumetric CT of the
liver and TLV is calculated using a formula for the correlation
between TLV and body surface area, which accounts for
individual liver metabolic demand.[59] The presence of
underlying liver disease is important because a severely
damaged liver is unable to regenerate. Both cirrhosis and
severe steatosis are causing significantly impair of the liver
regeneration after major hepatectomy. The use of PVE in these
conditions allows enlargement of the free of metastases liver,
although more slowly than in the healthy liver, reducing the
risks from the subsequent hepatectomy. Liver enlargement is
still followed by a nonlinear kinetic profile for the first 2
months of the POI. The largest increase in liver volume (75%)
occurs within 3 weeks after PVE, after which a plateau phase
is reached with minimal regeneration. It was recently shown
that hypertrophy occurs to the rest of the liver after PVE by
two complementary mechanisms - increased proliferation and
hypertrophy of hepatocytes.[62] Thus, the optimal time to
evaluate the hypertrophy after PvE is 3 to 4 weeks. Volumetric
CT can be repeated at this time because it provides two key
pieces of information: (1) if adequate liver volume has been
reached; (2) growth rate, which is informative for the liver
capacity for regeneration. We found that patients who had
slower liver hypertrophy have much worse clinical outcome
regardless of whether the target sFLR was achieved. The
volume of the remnant liver significantly varies from patient
to patient. In patients with an otherwise normal liver, PVE is
indicated when the sFLR <20%. sFLR less than 20% leads to
a significant increase in postoperative morbidity. Patients who
received preoperative chemotherapy or with extensive
steatosis, liver regeneration, a greater liver remnant more than
30% is proposed. Finally, in patients with liver cirrhosis, PVE
is indicated when sFLR is <40%.[14] Contraindications for PVE
include tumor invasion of the portal vein, portal vein
thrombosis, coagulopathy incorrigible, dilated biliary the RPF,
severe portal hypertension and renal failure.
Double-stage hepatectomy
Resection of multiple bilobar CLM can reduce
excessive reduction of the FLR, which in turn can lead to liver
failure postoperatively. In 2000, Adam et al.[63] proposed a
new two-stage approach for initially resectable liver tumors.
The maximum number of tumors removed in the first
operation, and a second surgery is performed to remove the
rest after a period of liver regeneration. The goal of the double-
stage hepatectomy is to minimize the risk of liver failure after
massive hepatectomy in patients with bilateral metastases. At
our institute, we have reversed the approach to perform small
resections at the first step usually in the remnant liver, and
later extended resections at the second stage with or without
PVE. This approach allows us to perform major surgery and
resection of the primary tumor in the first phase, with low
morbidity and subsequent major resection. The need for
temporary chemotherapy or PVE can be evaluated before the
following major resection. This approach was proposed by
Jaeck et al.[64] who recently applied systematic approach
based on two-stage hepatectomy with or without preoperative
PVE for a curative resection for CLM. They reported 1- and
3-year survival rate of 70% and 54.4%. The two-step strategy
for patients should not be entitled to an R0 resection in the
process under consideration. However, it maintains the criteria
for selection and use of preoperative chemotherapy in patients
with multiple bilobar CLM and are clarified.
Repeat hepatectomy
Most patients who undergo liver resection for CLM
have recurrence, and one third of these recurrences develop
only in the liver. Selected patients with isolated hepatic
recurrence may undergo repeat hepatectomy and achieve236  / JofIMAB 2012, vol. 18, book 1 /
long-term survival. After the third hepatectomy, survival rates
at 5 years are estimated as 32% and postoperative morbidity
and mortality are not higher than after the first
hepatectomy.[65] As bilobar multiple CLM recurrence are very
likely for recurrence, early diagnosis of the relapse is
important to maximize the number of patiets appropriate for
resection, and long-term survival can be achieved with this
approach.
Radiofrequency ablation
Unfortunately, not all patients are suitable for liver
resection for CLM and alternative therapies have been
proposed. The most common alternative treatment for CLM
is radiofrequency ablation (RFA). RFA involves placing an
electrode into the liver tumor under radiological guidance
(ultrasound [U.S.], CT or MRI), thermal (radio frequency)
energy generated, which destroys the tumor and a margin of
normal parenchyma. RFA can be performed percutaneously,
laparoscopically or during laparotomy. The use of RFA of
liver metastases was reported to be effective and safe by
many authors. Larger follow-up data confirm the safety
process, but suggest that RFA may not be equivalent to a
local resection as a modality.[8] A study by Abdalla et al is
comparing surgical resection vs RFA vs. a combined
procedure (resection and ablation) for CLM, and found a 5-
years recurrence rate after RFA to be higher compared to
combined procedure or resection alone (84%, 64% and 52%).
Limited hepatic recurrence after RFA is four times higher than
after resection. Therefore, the long-term survival after
resection is better then after local ablation (65% vs 22%) [8]
The same group studied solitary CLM and showed that liver
resection is associated with greater survival rates.[66] Local
recurrence are significantly lower after resection (5%)
compared to after RFA (37%) for solitary CLM and the rate
of 5-year survival was significantly longer after resection
(71%) compared to after RFA (27%). Baere et al. have been
reported in a large study procedure-related death in West
Germany around 2%.[67] Some authors have reported altered
patterns of recurrence of growth after RFA, including
sarcomatous and disseminated spread.[68] If such a
recurrence is appropriate for resection, an aggressive
approach is usually required, which increases postoperative
morbidity and mortality. Based on previous experience with
RFA, if a surgical resection is the treatment of choice for CLM,
with RFA reserved only for patients excluded from surgery
because of general contraindications like severe underlying
liver disease, recovery after surgery, or technically
unresectable limited disease. Because of poorer results with
RFA and the availability of multiple modalities of resection,
patients must always be submitted to the hepatobiliary
surgeon for expertise to determine their suitability for
resection before consideration of RFA.
CONCLUSION
Liver surgeons and oncologists should collaborate to
evaluate patients with CLM in order to individualize treatment
strategies and to optimize the chances of long-term survival.
Today, using a multi-disciplinary and multi-modal and a
variety of techniques available, it is possible for CLM to be
managed successfully and provide many patients with long
term survival. The increased acceptance of the hepatic
resection in the management of CLM in the medical
community and in the public undoubtedly leads to the
development of standardized protocols for screening the
population, patients, bowel resection, currently used in
specialized units. Improving early detection of CLM will lead
to increased respectability and improved results.
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